Roger Kitterman
Vice President, Venture @ Mass Medical Angels
Boston, United States
Roger Kitterman is a Series A investor at Mass Medical Angels in Boston focused on Health Care and Biotechnology. Roger is an experienced venture capital investor with more than 15 years in the industry and has guided multiple venture-backed companies through the earliest stages of development. He has also been the startup CEO for three venture-backed companies and is a founder of Mass Medical Angels. Previously, he was a general partner at Mi3 VenturePartners, an early stage, bioengineering focused fund. Prior to joining Mi3, he was a managing director at Lee Munder Venture Partners, the venture capital arm of Lee Munder Capital Group. He joined Lee Munder from Boston University’s Community Technology Fund, where he made venture capital investments in the life sciences and developed and managed spinouts from the university and Boston Medical Center. Roger began his venture capital career in Eastern Europe with the Bulgarian- American Enterprise Fund, a $55 million venture capital fund.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Roger Kitterman invests in
Stages Roger Kitterman invests in
Countries Roger Kitterman invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (40%)
- Biotechnology 2 (40%)
- Medical Device 1 (20%)
- Pharmaceutical 1 (20%)
- Health Diagnostics 1 (20%)
Stage
- Series A 2 (40%)
- Series B 1 (20%)
- Series D 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Daktari Diagnostics
|
Daktari Diagnostics was founded to create products that address the most pressing challenges in global health. These problems include not only better diagnosis of disease, but also the communication of data throughout the healthcare system.We are committed to delivering critical diagnostic test results to clinicians and patients across theglobe. Our team of engineers, scientists, physicians, and global health experts is uniquely dedicated to making high-performance products specifically designed for resource-poor markets.We recognize that information can only be useful if it can move. Daktari’s products are connected in the field, allowing clinical, quality, and performance data to flow where it needs to go.We strive to provide quality products at an affordable price, and to support our products when used by anyone, anywhere in the world. We strive to treat our customers, our partners, and our colleagues with kindness, as equals, and to be a positive force in our communities and in the world. | Series D / Mar 02, 2015 | |
|
Daktari Diagnostics
|
Daktari Diagnostics was founded to create products that address the most pressing challenges in global health. These problems include not only better diagnosis of disease, but also the communication of data throughout the healthcare system.We are committed to delivering critical diagnostic test results to clinicians and patients across theglobe. Our team of engineers, scientists, physicians, and global health experts is uniquely dedicated to making high-performance products specifically designed for resource-poor markets.We recognize that information can only be useful if it can move. Daktari’s products are connected in the field, allowing clinical, quality, and performance data to flow where it needs to go.We strive to provide quality products at an affordable price, and to support our products when used by anyone, anywhere in the world. We strive to treat our customers, our partners, and our colleagues with kindness, as equals, and to be a positive force in our communities and in the world. | Series B / Dec 30, 2011 | |
|
Daktari Diagnostics
|
Daktari Diagnostics was founded to create products that address the most pressing challenges in global health. These problems include not only better diagnosis of disease, but also the communication of data throughout the healthcare system.We are committed to delivering critical diagnostic test results to clinicians and patients across theglobe. Our team of engineers, scientists, physicians, and global health experts is uniquely dedicated to making high-performance products specifically designed for resource-poor markets.We recognize that information can only be useful if it can move. Daktari’s products are connected in the field, allowing clinical, quality, and performance data to flow where it needs to go.We strive to provide quality products at an affordable price, and to support our products when used by anyone, anywhere in the world. We strive to treat our customers, our partners, and our colleagues with kindness, as equals, and to be a positive force in our communities and in the world. | $2.8M / Series A / Oct 27, 2009 | |
|
Daktari Diagnostics
|
Daktari Diagnostics was founded to create products that address the most pressing challenges in global health. These problems include not only better diagnosis of disease, but also the communication of data throughout the healthcare system.We are committed to delivering critical diagnostic test results to clinicians and patients across theglobe. Our team of engineers, scientists, physicians, and global health experts is uniquely dedicated to making high-performance products specifically designed for resource-poor markets.We recognize that information can only be useful if it can move. Daktari’s products are connected in the field, allowing clinical, quality, and performance data to flow where it needs to go.We strive to provide quality products at an affordable price, and to support our products when used by anyone, anywhere in the world. We strive to treat our customers, our partners, and our colleagues with kindness, as equals, and to be a positive force in our communities and in the world. | $2.8M / Series A / Oct 27, 2009 | |
TargAnox
|
TargAnox develops drugs that help treat oncology and metabolic related inllnesses. | $5.1M / Series A / Mar 14, 2009 |
Co-Investors
About Mass Medical Angels
Mass Medical Angels (MA2) was founded to answer the need for a dedicated life-science centric angel group in New England. The Boston area is a world-leading supercluster for medical innovation, but all early-stage companies in the field have tremendous difficulty with first round funding. Their goal is to provide money and mentoring to the lifescience community to achieve superior returns for their group, and more clinical innovation for the community.
Mass Medical Angels Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Penny Rossano
Chair - Screening
|
|||
|
Roger Kitterman
Vice President, Venture
|
|||
David A. Fogel
Member / Member of Screening, Due Diligence Committees
|
|||
David Fogel
Member / Member of Screening, Due Diligence Committees
|
|||
Fred Mermelstein
Member
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Roger Kitterman invest in?
Roger Kitterman invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Roger Kitterman?
Public channels for Roger Kitterman include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Roger Kitterman last invest?
The most recent investment recorded for Roger Kitterman closed in Mar 2015. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
